All posts by Thomas Schneckenburger

Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic

By | Uncategorized | No Comments

Phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in Chicago. These data underline that abicipar has the potential to become the first fixed 12-week anti-VEGF therapeutic.

Read More

Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018: Promising MP0250 clinical data in oncology and positive abicipar phase 3 efficacy data presented

By | Uncategorized | No Comments

Molecular Partners announces its unaudited financial results for the first half-year 2018, including promising updated data on the phase 2 trial of its lead oncology asset MP0250 and the positive phase 3 topline data for abicipar, as announced on July 19, 2018 by the company’s strategic partner Allergan.

Read More